Back

Notification report


Full notification file


General information

Notification Number
B/DE/11/PEI1393

Member State to which the notification was sent
Germany

Date of acknowledgement from the Member State Competent Authority
27/06/2011

Title of the Project
VXM01 phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01

Proposed period of release:
01/11/2011 to 30/10/2012

Name of the Institute(s) or Company(ies)
VAXIMM GmbH, MAFINEX-Technologiezentrum
Julius-Hatry-Stra├če 1
68163 Mannheim;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
Bacterium

Identity of the GMO:
Proteobacteria, Gammaproteobacteria

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
S.typhi Ty21aEnterobacteriaceaesalmonellaentericaTy21aSerotype Typhi

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known